The incidence of interstitial lung disease was higher in the group treated with the GLP-1 receptor agonist, while the effect was neutral for lung adenocarcinoma and obstructive sleep apnea. The gene discussed is GLP1R; the disease is obstructive sleep apnea syndrome.